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Abstract
Background: About one quarter of adults are hypertensive and high blood pressure carries increased risk for heart
disease, stroke, kidney disease and death. Increased arterial stiffness is a key factor in the pathogenesis of systolic
hypertension and cardiovascular disease. Substantial heritability of blood-pressure (BP) and arterial-stiffness suggests
important genetic contributions.
Methods: In Framingham Heart Study families, we analyzed genome-wide SNP (Affymetrix 100K GeneChip) associations
with systolic (SBP) and diastolic (DBP) BP at a single examination in 1971–1975 (n = 1260), at a recent examination in
1998–2001 (n = 1233), and long-term averaged SBP and DBP from 1971–2001 (n = 1327, mean age 52 years, 54%
women) and with arterial stiffness measured by arterial tonometry (carotid-femoral and carotid-brachial pulse wave
velocity, forward and reflected pressure wave amplitude, and mean arterial pressure; 1998–2001, n = 644). In primary
analyses we used generalized estimating equations in models for an additive genetic effect to test associations between
SNPs and phenotypes of interest using multivariable-adjusted residuals. A total of 70,987 autosomal SNPs with minor
allele frequency ≥ 0.10, genotype call rate ≥ 0.80, and Hardy-Weinberg equilibrium p ≥ 0.001 were analyzed. We also
tested for association of 69 SNPs in six renin-angiotensin-aldosterone pathway genes with BP and arterial stiffness
phenotypes as part of a candidate gene search.
Results: In the primary analyses, none of the associations attained genome-wide significance. For the six BP phenotypes,
seven SNPs yielded p values < 10-5. The lowest p-values for SBP and DBP respectively were rs10493340 (p = 1.7 × 
10-6) and rs1963982 (p = 3.3 × 10-6). For the five tonometry phenotypes, five SNPs had p values < 10-5; lowest p-values
were for reflected wave (rs6063312, p = 2.1 × 10-6) and carotid-brachial pulse wave velocity (rs770189, p = 2.5 × 10-6)
in MEF2C, a regulator of cardiac morphogenesis. We found only weak association of SNPs in the renin-angiotensin-
aldosterone pathway with BP or arterial stiffness.
Conclusion: These results of genome-wide association testing for blood pressure and arterial stiffness phenotypes in
an unselected community-based sample of adults may aid in the identification of the genetic basis of hypertension and
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needed to replicate any associations identified in these analyses.
Background
Hypertension affects about one quarter of adults in indus-
trialized countries [1] and carries a substantial burden of
risk for cardiovascular disease (CVD), kidney disease, and
death [2]. Increased arterial stiffness is a key factor in the
pathogenesis of hypertension in older people and it con-
tributes to the development of hypertensive target organ
damage, CVD, and death [3-5]. Substantial heritability of
blood pressure [6] and arterial stiffness [7]), as measured
by arterial tonometry, points to genetic contributions to
these cardiovascular phenotypes.
The search for genetic variants contributing to hyperten-
sion and arterial stiffness has focused on complementary
approaches: linkage applied to rare Mendelian blood
pressure disorders and to large family-based studies to
identify positional candidate genes, and the study of bio-
logically plausible candidate genes selected by virtue of
their role in blood pressure regulation or vascular proper-
ties. A great deal is known about mutations responsible
for Mendelian blood pressure disorders [8], but neither
these rare variants nor more common variants in these
genes account for substantial blood pressure variation in
the general population. Similarly, although numerous
linkage [9] and candidate gene association studies [10]
have been conducted, there is a paucity of evidence that
common genetic variation contributes to alterations in
blood pressure or arterial stiffness in the general popula-
tion.
Genome-wide association offers the opportunity to con-
duct analysis of common genetic variants unconstrained
by prior knowledge of biological pathways in relation to
phenotypes of interest. This approach succeeded in iden-
tifying the association of complement factor H with age-
related macular degeneration [11]. The Framingham
Heart Study, which enrolled participants without regard
to phenotype status, provides a setting for a genome-wide
association study in a community-based sample in which
selection bias is inherently low. In addition, because of
the familial structure of the study, it also provides an
opportunity to use genome-wide SNP data for family
based association testing (FBAT) and linkage analyses.
In this report we provide results of a genome-wide associ-
ation study of blood pressure and arterial stiffness, includ-
ing results of generalized estimating equation (GEE)
association testing, FBAT, and linkage, as well as a sum-
mary of associations of these phenotypes with candidate
genes in the renin-angiotensin-aldosterone pathways.
Methods
Study sample
The Framingham Heart Study began in 1948 when 5209
men and women from Framingham, Mass, who were
between 28 and 62 years of age were recruited to partici-
pate in an observational study [12]. Subjects underwent a
medical history, physician-administered physical exami-
nation including blood pressure measurement, laboratory
tests, and electrocardiography. Examinations have been
repeated every 2 years. In 1971, 5124 offspring and
spouses of offspring of original participants were recruited
into the Framingham Offspring Cohort [13]. The off-
spring cohort was reexamined approximately every 4
years, except for an 8 year interval between their initial
and second visit. All subjects gave written informed con-
sent before each clinic visit, and the examination protocol
was approved by the Institutional Review Board at Boston
Medical Center (Boston, Mass).
Blood pressure phenotypes
At each clinic visit, the examining physician measured the
systolic and diastolic BP in the left arm using a mercury
column sphygmomanometer. BP was measured twice at
each visit, with the exception of the first Offspring Cohort
clinic visit, when it was measured once in about half the
participants. Systolic and diastolic pressures were deter-
mined by the first and fifth Korotkoff sounds, respectively,
and the two BP measurements were averaged to derive the
systolic and diastolic pressures for that examination.
Examination cycles for the two cohorts were overlaid tem-
porally as follows [offspring cohort/original cohort (earli-
est - latest year)]: examination 1/examination 12 (1971–
1975), examination 2/examination 16 (1979–1983),
examination 3/examination 18 (1983–1987), examina-
tion 4/examination 20 (1986–1991), examination 5/
examination 22 (1990–1995), examination 6/examina-
tion 24 (1995–1998) and examination 7/examination 26
(1998–2001). Referring to offspring cycle numbers, the
six BP phenotypes analyzed for this investigation were
residuals for SBP and DBP at Examination 1, at Examina-
tion 7, and average of residuals from available Examina-
tions 1 to 7. BP was imputed for treated observations as
previously described [6]. No adjustment was made for
untreated observations, which constituted the vast major-
ity of BP values. Systolic and diastolic BP phenotypes were
analyzed independently. Residuals were obtained from
cohort- and examination-specific regression models
accounting for sex, age and BMI; for DBP, age-squared was
added. For inclusion in long-term BP analyses, each par-Page 2 of 11
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nations over a period of 12 years or more.
Arterial stiffness phenotypes
Arterial tonometry for assessment of arterial stiffness was
conducted on Offspring Cohort participants attending
their 7th clinic examination. Five primary tonometry phe-
notypes were analyzed: carotid-femoral and carotid-bra-
chial pulse wave velocity, forward and reflected pressure
wave amplitude, and mean arterial pressure. Tonometry
was performed in the supine position after 5 minutes of
rest. Arterial tonometry with simultaneous ECG recording
was obtained from brachial, radial, femoral and carotid
arteries using a commercially available tonometer (SPT-
301, Millar Instruments, Houston, TX). Carotid-brachial,
carotid-radial and carotid-femoral PWV were calculated as
previously described [14]. Mean arterial pressure was cal-
culated from the planimetered brachial arterial tracing
after calibration to the brachial blood pressure, which was
obtained by an oscillometric device. Forward pressure
wave amplitude was defined as the difference between
pressure at the waveform foot and pressure at the first
systolic inflection point or peak of the carotid pressure
waveform; reflected pressure wave amplitude was defined
as the difference between the central systolic pressure and
the pressure at the forward wave peak. Sex-specific regres-
sions were conducted for each tonometry phenotype with
the following covariates: age, age2, height, weight, to gen-
erate sex-specific residuals.
Genotyping methods
Details of the genotyping methods are available in the
Executive Summary [15]. Briefly, 112990 autosomal SNPs
on the Affymetrix 100K chip were genotyped in the Bos-
ton University School of Medicine Genetics Laboratory on
the Framingham Heart Study family plate set. SNPs were
excluded for the following reasons: minor allele frequency
<10% (n = 38062); call rate <80% (n = 2346); Hardy
Weinberg equilibrium p value < 0.001 (n = 1595), leaving
70,987 SNPs available for analysis.
Statistical methods
Standardized multivariable-adjusted blood pressure and
tonometry residuals were generated as described above.
Table 1 lists the covariates used for each phenotype. As
described in the Executive Summary [15], we conducted
association testing using family based association testing
(FBAT), and generalized estimating equations (GEE)
applied to the additive genetic effects model. In secondary
analyses that used the GEE general genetic effects model,
which is more sensitive to recessive genetic effects, to be
more conservative, we limited analyses to two pheno-
types: long-term SBP and long-term DBP, and we limited
eligible SNPs to those with a minor allele frequency >=
0.20 and Hardy-Weinberg equilibrium p value >= 0.05.
The software package Merlin [16] was used to compute
exact identity by descent linkage probabilities for allele
sharing, and linkage analysis by variance component
method was carried out SOLAR using 11,200 SNPs and
STRs. Heritability was estimated using variance-compo-
nents methods (SOLAR). For BP, 2155 study participants
were used for examination 1 SBP and DBP, 1479 for
examination 7, and 2009 for long-term average; 770 indi-
viduals were used in heritability analysis of arterial stiff-
ness phenotypes.
Candidate gene analyses
GEE and FBAT additive genetic effect models were run for
SNPs in or near 6 genes in the renin-angiotensin-aldoster-
one pathways. These genes were selected a priori because
of a substantial body of literature implicating them in
hypertension and altered vascular properties. All SNPs
from 200 Kb proximal to the start and extending to 200 kb
of the terminus of each gene were included in analysis
providing the minor allele frequency was >= 0.1, the gen-
otype call rate was 0.8, and the Hardy-Weinberg equilib-
rium p value was >= 0.001.
Results
The six primary BP phenotypes were examination 1 SBP
and DBP (n = 1260), examination 7 SBP and DBP (n =
1233), and long-term averaged SBP and DBP (n = 1327).
The five primary arterial stiffness phenotypes were
carotid-femoral and carotid-brachial pulse wave velocity,
forward and reflected pressure wave amplitude, and mean
arterial pressure (n = 644). The study sample available for
BP phenotypes included up to 1327 individuals (mean
age 52 years, 54% women for the long-term SBP and DBP
phenotypes). The complete list of blood pressure and arte-
rial stiffness phenotypes analyzed and the covariates used
in generating sex-specific standardized residuals for each
phenotype are listed in Table 1. Full disclosure of all GEE
and FBAT associations for the traits listed in Table 1 can be
found at the National Center for Biotechnology Informa-
tion dbGaP website: http://web.ncbi.nlm.nih.gov/
projects/gap/framingham/cgi-bin/
study.cgi?id=phs000007.
Results of primary GEE models for an additive genetic
effect for DBP, SBP, and arterial stiffness phenotypes are
presented in Table 2a. None of the association results
attained genome-wide significance. The lowest p values
for DBP, SBP, and arterial stiffness phenotypes, respec-
tively, were rs1963982 (p = 3.31 × 10-6), rs10493340 (p =
1.7 × 10-6), and rs6063312 (p = 2.1 × 10-6 for reflected
wave amplitude). For the same three phenotype groups
the number of associations with p values < 10-5 were 6, 1,
and 5, respectively.Page 3 of 11
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Table 1: Phenotype List
Exam cycle/s
N* Offspring Cohort Adjustment Covariates
Primary Phenotypes
Blood Pressure
SBP 1 2 1 12 Age and sex, multivariable Cohort, sex, age, BMI
SBP 7 2 7 26 Age and sex, multivariable Cohort, sex, age, BMI
SBP 1–7 2 Mean of exams 1–7 Mean of exams 12, 16, 18, 20, 22, 24, 26 Age and sex, multivariable Cohort, sex, age, BMI
DBP 1 2 1 12 Age and sex, multivariable Cohort, sex, age, BMI
DBP 7 2 7 26 Age and sex, multivariable Cohort, sex, age, BMI
DBP 1–7 2 Mean of exams 1–7 Mean of exams 12, 16, 18, 20, 22, 24, 26 Age and sex, multivariable Cohort, sex, age, BMI
Tonometry
Carotid-femoral PWV 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
Carotid-brachial PWV 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
Forward pressure wave 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
Reflected pressure wave 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
Mean arterial pressure 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
Secondary Phenotypes^
Blood Pressure
DBP 2 2 2 16 Age and sex, multivariable Cohort, sex, age, BMI
DBP 3 2 3 18 Age and sex, multivariable Cohort, sex, age, BMI
DBP 4 2 4 20 Age and sex, multivariable Cohort, sex, age, BMI
DBP 5 2 5 22 Age and sex, multivariable Cohort, sex, age, BMI
DBP 6 2 6 24 Age and sex, multivariable Cohort, sex, age, BMI
SBP 2 2 2 16 Age and sex, multivariable Cohort, sex, age, BMI
SBP 3 2 3 18 Age and sex, multivariable Cohort, sex, age, BMI
SBP4 2 4 20 Age and sex, multivariable Cohort, sex, age, BMI
SBP 5 2 5 22 Age and sex, multivariable Cohort, sex, age, BMI
SBP 6 2 6 24 Age and sex, multivariable Cohort, sex, age, BMI
PP 1 2 1 12 Age and sex, multivariable Cohort, sex, age, BMI
PP 2 2 2 16 Age and sex, multivariable Cohort, sex, age, BMI
PP 3 2 3 18 Age and sex, multivariable Cohort, sex, age, BMI
PP 4 2 4 20 Age and sex, multivariable Cohort, sex, age, BMI
PP 5 2 5 22 Age and sex, multivariable Cohort, sex, age, BMI
PP 6 2 6 24 Age and sex, multivariable Cohort, sex, age, BMI
PP 7 2 7 26 Age and sex, multivariable Cohort, sex, age, BMI
PP 1–7 2 Mean of exams 1–7 Mean of exams 12, 16, 18, 20, 22, 24, 26 Age and sex, multivariable Cohort, sex, age, BMI
Tonometry
1/CF-PWV 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
AI 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
CPP 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
CR-PWV 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
DBP-osc 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
PA-1 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
PA-2 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
PP-osc 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
RWTT 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
SBP-osc 2 7 Not included Age and sex, multivariable Sex, age, age^2, height, weight
*n = number of phenotypes analyzed
^Association results for primary and secondary phenotypes are available on the worldwide web at: http://web.ncbi.nlm.nih.gov/projects/gap/
framingham/cgi-bin/study.cgi?id=phs000007
AI = augmentation index; CPP = central pulse pressure; CB-PWV = carotid brachial pulse wave velocity; CF-PWV = carotid-femoral pulse wave 
velocity; CR-PWV = carotid-radial pulse wave velocity; DBP = diastolic blood pressure; DBP-osc = brachial DBP by oscillometric device; FW = 
forward wave amplitude; MAP = mean arterial pressure; PA-1 = apparent peripheral amplification; PA-2 = true peripheral amplification; PP = pulse 
pressure; PP-osc = brachial PP by oscillometric device; RW = reflected wave amplitude; RWTT = reflected wave transit time; SBP = systolic blood 
pressure; SBP-osc = brachial SBP by oscillometric device; 1/CF-PWV = inverse of CF-PWV.
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Table 2b. Two SNPs for DBP and one for SBP yielded p
values < 10-5. Of note, rs10520569 in ADAMTSL3 was
associated with DBP (4.2 × 10-5) and SBP (1.4 × 10-4). For
arterial stiffness phenotypes there were 2 p values < 10-5,
including rs792833 in COL8A1.
Linkage analyses (Table 2c) yielded a LOD score of 3 for
long-term SBP on chromosome 15 at 100 Mb. Several
tonometry linkage peaks exceeded a LOD score of 3,
including a LOD of 5.0 for reflected wave (chromosome 8
at 19 Mb). Heritability estimates (Table 2d) were high for
long-term average DBP (h2 = 0.55) and SBP (h2 = 0.57),
and intermediate for the other BP phenotypes (h2 = 0.28–
0.45). Among the arterial stiffness phenotypes, heritabil-
ity was high for the reflected arterial waveform (h2 = 0.66),
low for carotid-brachial PWV (h2 = 0.02), and intermedi-
ate for the other phenotypes (h2 = 0.22–0.43). These her-
itability results are consistent with our prior findings
[6,7].
Secondary analyses using the GEE general genetic effects
model (2 degrees of freedom; more sensitive in detecting
recessive effects) are presented in Table 3. The lowest p
value for long-term DBP was in CCL20 (rs7591163, p =
2.3 × 10-7) and for SBP was in CDH13 (rs3096277, p = 9.9
× 10-8). Of note, SNPs in CDH13, CCL20, and WDR69
were associated with DBP and SBP. GEE general effects
models for the tonometry phenotypes identified associa-
tion of mean arterial pressure with TGFBR2 (rs3773643, p
= 2 × 10-7).
Geometric means of GEE association results (additive
genetic effect model) for SBP and DBP considered jointly
are summarized in Table 4. The lowest p values were
noted for Examination 1 BP values (rs10493340, p = 1.5
× 10-5). Geometric means of association results for the 5
tonometry phenotypes considered concurrently yielded
its lowest p value (rs10518082, p = 0.002) for DCK.
SNPs in 6 renin-angiotensin-aldosterone pathway genes
were analyzed for association with the BP and tonometry
phenotypes (Table 5). A total of 69 SNPs qualified for
analysis (minor allele frequency >= 0.1, Hardy Weinberg
equilibrium p >= 0.001, call rate >= 0.8). For the primary
traits there were few associations from GEE models for an
additive genetic effect with p values < 0.05 and none with
p < 0.001.
Discussion and conclusion
We provide results of genome-wide association study for
6 blood pressure and 5 arterial stiffness phenotypes in a
carefully characterized study sample. Association analyses
and linkage reveal a number of intriguing results. For the
GEE model of additive genetic effects (Table 2a) there
were 7 SNPs with p values < 10-5 for blood pressure and 5
for arterial stiffness phenotypes. Among the GEE additive
effect model results the most likely candidate genes were
MEF2C, SYNE1, and TNFSF11, which were associated
with arterial stiffness. We have not yet attempted replica-
tion of our results. Follow-up genotyping of the top SBP
and DBP SNPs reported in our study sample in additional
Framingham participants is planned; additional replica-
tion attempts will be needed in independent samples to
confirm any of the association results we report.
FBAT (Table 2b) identified association of COL8A1 with
arterial stiffness (p value 6 × 10-6 for rs792833). This gene
codes for type VIII collagen, which is produced by aortic
endothelial cells [17], suggesting a biologically plausible
association.
Linkage yielded a LOD score of 3, approaching genome-
wide significance, for long-term SBP on chromosome 15.
A meta-analysis of blood pressure and hypertension link-
age studies did not identify this as a region of interest [9].
The lower LOD scores for long-term SBP on chromosome
17 (~67 cM) in this investigation compared with our prior
findings [6] appears to be largely due to differences in
phenotype definition of long-term SBP with the exclusion
of early examination BP values in the original cohort par-
ticipants and the inclusion of offspring cohort examina-
tion 7 blood pressures in this analysis. When linkage
analyses were repeated with the inclusion of the early orig-
inal cohort exams using the prior phenotype definitions,
the same linkage peak on chromosome 17 emerged (LOD
> 4).
For tonometry phenotypes, we found LOD scores for
reflected wave amplitude of 5.0 (chromosome 8 at 19
Mb) and 3.2 (chromosome 4, 169 Mb) near peaks for this
phenotype that we previously reported in a largely over-
lapping study sample [7]. Similarly, we once again identi-
fied a linkage peak for carotid-femoral pulse wave velocity
(LOD 3.0; chromosome 2 at 74 mb).
Compared with the primary GEE model for additive
genetic effects (Table 2a), a different set of SNPs was iden-
tified in secondary GEE general effects models (Table 3)
for long-term DBP and SBP, including 2 SNPs with p val-
ues < 10-6. Differences in model results may be due to the
greater sensitivity of the general model to detect recessive
genotype effects. SNPs in CCL20, CDH13, and LPP were
associated with both long-term SBP and DBP. GEE general
genetic effects models for arterial stiffness phenotypes
yielded the lowest p value (p = 1.99 × 10-7) for rs3773643
in TGFBR2, which has been implicated in aortic aneurysm
and Loeys-Dietz syndrome [18,19]. Disruption of the aor-
tic wall would be expected to affect arterial stiffness.Page 5 of 11
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Stiffness Phenotypes
2a. Results of GEE Additive Genetic Effects Models
Phenotype Exam SNP Chr. Position GEE P value FBAT P value Gene
Diastolic Blood Pressure
DBP 7 rs1963982 8 73,269,470 3.31 × 10-6 0.002
DBP 1 rs935334 14 75,683,431 3.32 × 10-6 0.002
DBP 7 rs4370013 3 2,629,691 3.73 × 10-6 0.032 CNTN4
DBP 7 rs10491334 5 110,800,303 4.47 × 10-6 0.133 CAMK4
DBP 1 rs2121070 14 75,720,517 4.88 × 10-6 0.02 C14orf118
DBP 1 rs2509458 6 88,709,299 6.94 × 10-6 0.001
DBP 7 rs6950982 7 100,360,038 1.22 × 10-5 0.036 TRIM56, SERPINE1, AP1S1
DBP 7 rs10510911 3 63,678,681 1.65 × 10-5 0.021
DBP 1 rs1816088 5 39,897,583 1.73 × 10-5 0.012
DBP 7 rs1519592 6 140,585,329 1.89 × 10-5 2.83 × 10-4
Systolic Blood Pressure
SBP 1 rs10493340 1 63,303,150 1.69 × 10-6 0.13
SBP 7 rs1841055 4 70,039,785 2.07 × 10-5 0.003 UGT2A3
SBP 1 rs2035254 3 107,292,420 2.20 × 10-5 0.046
SBP 1–7 rs1408263 6 18,515,722 2.43 × 10-5 0.121 IBRDC2
SBP 7 rs1408113 9 113,822,387 2.54 × 10-5 0.034 ZNF618
SBP 7 rs629448 9 26,263,322 3.14 × 10-5 0.011
SBP 7 rs10485320 6 47,884,860 3.28 × 10-5 0.012 OPN5
SBP 7 rs10512889 5 6,921,922 4.17 × 10-5 0.008
SBP 1 rs1328925 4 159,547,895 4.32 × 10-5 0.118 TMEM144
SBP 7 rs9321764 6 140,532,157 4.39 × 10-5 4.76 × 10-4
Tonometry Phenotypes
RW 7 rs6063312 20 46,776,466 2.09 × 10-6 0.063 PREX1
CB-PWV 7 rs770189 5 88,124,195 2.53 × 10-6 0.005 MEF2C
CB-PWV 7 rs10514688 3 34,937,673 5.66 × 10-6 0.027
CB-PWV 7 rs7042864 9 107,951,862 6.13 × 10-6 0.077
MAP 7 rs1322512 6 153,040,067 7.76 × 10-6 0.038 SYNE1
FW 7 rs348384 19 6,503,386 1.16 × 10-5 0.058 TUBB4, TNFSF9, TNFSF7
RW 7 rs10507514 13 42,132,814 1.28 × 10-5 0.066 TNFSF11
FW 7 rs3793427 8 17,188,201 1.43 × 10-5 0.059 VPS37A
RW 7 rs10506928 12 85,003,844 1.62 × 10-5 0.021
FW 7 rs4075701 2 116,146,020 1.63 × 10-5 0.025
RW 7 rs11784583 8 103,154,213 3.83 × 10-5 0.036
RW 7 rs10513957 18 65,039,417 4.15 × 10-5 0.019
CF-PWV 7 rs10506440 12 60,993,853 4.18 × 10-5 0.064 USP15
RW 7 rs1197850 13 34,828,744 4.57 × 10-5 0.042
2b. Results of FBAT Additive Genetic Effects Models
Phenotype Exam SNP Chr. Position GEE P value FBAT P Value Gene
DBP 1 rs1590919 13 104,000,000 0.079 1.42 × 10-6
DBP 1–7 rs636864 6 150,000,000 4.49 × 10-4 1.55 × 10-6
DBP 1 rs726698 2 35,366,992 0.02 1.15 × 10-5
DBP 7 rs1338657 6 103,000,000 0.001 2.57 × 10-5
DBP 1–7 rs10506595 12 69,191,621 0.133 3.40 × 10-5 PTPRB
DBP 7 rs9311171 3 37,971,481 0.025 4.03 × 10-5 CTDSPL
DBP 1 rs10520569 15 82,520,393 0.577 4.24 × 10-5 ADAMTSL3
DBP 7 rs4514016 8 120,000,000 3.70 × 10-5 4.52 × 10-5 SAMD12
DBP 7 rs2322509 8 27,052,291 0.172 4.91 × 10-5
DBP 1–7 rs10504389 8 66,718,741 0.1 5.53 × 10-5 ARMC1, MTFR1
SBP 1 rs1588260 5 121,000,000 0.001 3.43 × 10-6
SBP 1 rs726698 2 35,366,992 0.023 2.70 × 10-5
SBP 7 rs963328 1 209,000,000 0.036 3.01 × 10-5Page 6 of 11
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SBP 7 rs1434939 8 69,666,816 0.004 4.97 × 10-5
SBP 1–7 rs10498500 14 62,030,261 0.005 6.25 × 10-5
SBP 1 rs3853241 5 166,000,000 0.003 6.25 × 10-5
SBP 1–7 rs1590919 13 104,000,000 0.14 6.66 × 10-5
SBP 1 rs6763833 3 65,953,132 0.374 8.18 × 10-5 MAGI1
SBP 7 rs6940110 6 10,377,050 0.145 8.42 × 10-5
FW 7 rs1539377 9 81,441,976 5.48 × 10-5 5.26 × 10-6 TLE1
RW 7 rs792833 3 101,000,000 0.123 6.01 × 10-6 COL8A1
MAP 7 rs10495191 1 219,000,000 0.007 1.46 × 10-5 TAF1A
CB-PWV 7 rs10494786 1 196,000,000 0.079 1.56 × 10-5
CB-PWV 7 rs2160595 18 61,742,129 0.001 2.38 × 10-5 CDH7
FW 7 rs28899 5 82,798,839 0.001 2.99 × 10-5 VCAN
CF-PWV 7 rs1349721 4 86,693,958 0.105 3.34 × 10-5 ARHGAP24
CB-PWV 7 rs3001450 9 93,164,925 0.61 3.91 × 10-5 WNK2
CB-PWV 7 rs1389608 14 46,027,527 0.111 4.08 × 10-5
RW 7 rs10499221 6 141,000,000 0.003 5.92 × 10-5
2c. Linkage Results
Phenotype Exam LOD Chr. Position Lower bound* Upper bound
DBP 1–7 2.03 17 12,245,760 9,173,838 16,450,642
SBP 1–7 3 15 100,152,332 97,636,843 100,152,332
SBP 7 2.55 15 79,161,506 75,509,164 85,958,968
SBP 7 2.39 3 129,657,137 105,768,506 141,888,352
SBP 1–7 2.18 5 41,710,612 36,665,015 67,696,396
SBP 1–7 2.07 3 107,844,505 99,203,989 144,119,612
SBP 7 2.06 12 101,785,625 94,922,502 107,253,596
RW 7 5.02 8 19,102,897 17,257,073 21,506,898
RW 7 3.35 9 10,499,434 6,759,229 10,671,522
RW 7 3.17 4 169,091,021 162,723,480 170,955,956
CF-PWV 7 3.04 2 74,021,676 49,795,460 103,043,940
CF-PWV 7 2.68 18 40,229,747 38,788,852 43,206,229
FW 7 2.47 3 60,298,724 24,621,158 62,757,508
RW 7 2.47 15 100,152,332 94,749,239 100,152,332
CF-PWV 7 2.43 15 99,551,603 92,469,518 100,152,332
RW 7 2.29 1 12,153,078 4,266,833 17,528,974
CF-PWV 7 2.17 4 11,998,283 7,901,357 25,777,055
2d. Heritability of Blood Pressure and Arterial Stiffness Phenotypes
Phenotype Exam Heritability s.e.
DBP 1 0.3 0.04
DBP 7 0.35 0.06
DBP 1–7 0.55 0.05
SBP 1 0.28 0.04
SBP 7 0.45 0.06
SBP 1–7 0.57 0.04
CB-PWV 7 0.02 0.09
CF-PWV 7 0.43 0.1
FW 7 0.22 0.09
MAP 7 0.32 0.1
RW 7 0.66 0.1
Association results based on minor allele frequency >= 0.1, HWE p value >= 0.001, call rate >= 0.8
CB-PWV = carotid-brachial pulse wave velocity; CF-PWV = carotid-femoral pulse wave velocity; DBP = diastolic blood pressure; FW = forward wave amplitude; MAP = mean 
arterial pressure; RW = reflected wave amplitude; SBP = systolic blood pressure
*Lower and upper bounds for LOD-1.5 interval.
Table 2: Results of GEE and FBAT Additive Genetic Effects: Association, Linkage, and Heritability of Blood Pressure and Arterial 
Stiffness Phenotypes (Continued)Page 7 of 11
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nation r = 0.77; long-term r = 0.82), joint analyses of SBP
and DBP added little to what was identified in individual
phenotype analyses. In contrast, joint analyses of the five
tonometry phenotypes, which are less highly correlated,
identified LOXL2, SYNE1, and MEF2C as attractive candi-
dates. LOXL2 is a member of the lysyl oxidase family of
enzymes that initiate cross-linking of collagens and elas-
tin, and alter arterial elasticity [20]. Collagen and elastin
cross-links are critical to tensile strength of the extracellu-
lar matrix. Mice null for lysyl oxidase (LOX) die perina-
tally from aortic aneurysm [21]. MEF2C is involved in
cardiac morphogenesis and extracellular matrix remode-
ling [22]. SYNE1 is involved in aortic vascular smooth
muscle differentiation [23]. To our knowledge, genetic
variation in these genes has not previously been shown to
be associated with alterations in arterial properties in
humans. Whether our results provide nominal evidence
of such association or merely chance findings remains to
be determined.
Since none of the primary associations attained genome-
wide significance, this investigation should be viewed as
hypothesis generating. Association analyses for SNPs in
six renin-angiotensin-aldosterone pathway genes showed
weak evidence of association. Negative results for these
Table 3: Results of GEE General Genetic Effects Model for Long-term Average Blood Pressure Phenotypes and Arterial Stiffness
Phenotype SNP Chr. Position P value* Gene
Diastolic Blood Pressure (long-term average)
DBP rs7591163 2 228,423,620 2.90 × 10-7 CCL20, WDR69
DBP rs1901167 5 40,996,921 6.40 × 10-5 C7
DBP rs6829806 4 85,916,019 8.10 × 10-5 CDS1
DBP rs6796000 3 189,874,213 1.10 × 10-4 LPP
DBP rs3096277 16 82,321,705 1.40 × 10-4 CDH13
DBP rs969049 4 99,346,035 1.40 × 10-4
DBP rs10503497 8 14,326,753 1.40 × 10-4 SGCZ
DBP rs2262138 19 16,213,403 2.10 × 10-4 FAM32A, AP1M1
DBP rs10509333 10 72,737,658 3.70 × 10-4 UNC5B, SLC29A3
DBP rs933296 12 109,837,230 4.10 × 10-4 MYL2
Systolic Blood Pressure (long-term average)
SBP rs3096277 16 82,321,705 9.90 × 10-8 CDH13
SBP rs1721359 2 228,460,118 1.00 × 10-5 CCL20, WDR69
SBP rs225942 14 29,595,139 5.30 × 10-5 PRKD1
SBP rs298988 4 119,867,850 7.80 × 10-5 SEC24D
SBP rs10514096 5 76,700,940 1.10 × 10-4 PDE8B
SBP rs10512245 9 95,771,366 1.40 × 10-4
SBP rs294593 5 163,000,000 1.80 × 10-4 MAT2B
SBP rs6085660 20 6,639,069 1.90 × 10-4 BMP2
SBP rs6796000 3 190,000,000 2.20 × 10-4 LPP
SBP rs575121 12 117,000,000 2.20 × 10-4 TAOK3
Tonometry
MAP rs3773643 3 30,685,247 1.99 × 10-7 TGFBR2
FW rs3793427 8 17,188,201 1.96 × 10-6 VPS37A
RW rs6492654 13 92,688,671 2.28 × 10-6 GPC6
CF-PWV rs1367248 2 124,734,834 2.88 × 10-6 CNTNAP5
CF-PWV rs10521232 17 13,480,529 3.88 × 10-6 HS3ST3A1
FW rs3766680 1 173,563,0070 4.15 × 10-6 TNR
RW rs1371924 3 144,732,760 4.44 × 10-6 SLC9A9
RW rs10488172 7 132,985,716 8.49 × 10-6 EXOC4
FW rs10507534 13 44,724,220 1.05 × 10-5 GTF2F2
FW rs719856 6 47,702,681 1.21 × 10-5 CD2AP
*P values from 2 degree of freedom test
CB-PWV = carotid-brachial pulse wave velocity; CF-PWV = carotid-femoral pulse wave velocity; DBP = diastolic blood pressure; FW = forward 
wave amplitude; MAP = mean arterial pressure; RW = reflected wave amplitude; SBP = systolic blood pressure
Minor allele frequency >= 0.20, HWE P value >= 0.05, call rate >= 0.80Page 8 of 11
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disequilibrium coverage of these genes by the SNPs in this
genome-wide scan. It is likely that the vast majority of low
p values from association analyses are due to chance. Rep-
lication studies in other populations, using a genome-
wide approach or selective genotyping is needed to estab-
lish if any of our results are indicative of true positive asso-
ciations.
We provide results of genome-wide association testing for
blood pressure and arterial stiffness phenotypes obtained
in a carefully described community-based sample of
adults who were recruited without regard to disease status.
Additional studies are needed to validate these results.
Finding genetic variants associated with hypertension or
altered arterial properties may aid in the identification of
high risk individuals and in the development of new tar-
geted therapies for hypertension. Our report is one of the
earlier genome-wide association studies of blood pres-
sure. Several additional studies, some with larger sample
size and others with more dense genome-wide coverage of
common variation will follow. In that regard, a 550 k SNP
genome-wide association study in approximately 9400
Framingham Heart Study participants across three gener-
ations is underway and results from that study will help in
the interpretation of the findings we report in this manu-
script.
Abbreviations
DBP = diastolic blood pressure; FBAT = family based asso-
ciation test; GEE = generalized estimating equation; LOD
= log of the odds; SBP = systolic blood pressure; SNP = sin-
gle nucleotide polymorphism.
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REN 9 0
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